 |
Journal articles
Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse
Abstract : It is widely assumed that the upcoming therapeutics for Alzheimer's disease will require to act on more than one target to be effective. We investigated here whether a combination of the nicotinic receptor allosteric modulator/cholinesterase inhibitor galantamine can act synergistically with the type 4 serotonin receptor (5-HT4R) partial agonist, RS-67333, to counterbalance deficits in short- and long-term memory. To select sub-efficacious doses of both drugs, dose-response studies were first performed on the scopolamine-induced deficits of spontaneous alternation in the Y-maze task and of acquisition and retrieval processes in a passive avoidance task.
https://hal-normandie-univ.archives-ouvertes.fr/hal-02135214
Contributor : François Dauphin Connect in order to contact the contributor
Submitted on : Tuesday, May 21, 2019 - 10:09:37 AM
Last modification on : Tuesday, October 19, 2021 - 11:35:04 PM
Contributor : François Dauphin Connect in order to contact the contributor
Submitted on : Tuesday, May 21, 2019 - 10:09:37 AM
Last modification on : Tuesday, October 19, 2021 - 11:35:04 PM
